Advanced BioMatrix’s Post

New publication! 🎉 🧬 Targeting BRAFV600E with the Power of HPC The BRAFV600E mutation plays a key role in several cancers, including melanoma, thyroid, and colorectal cancer. In our latest study, we designed a new series of pyrimidine–sulfonamide hybrid molecules, inspired by existing BRAF inhibitors. Using high-performance computing (HPC), we ran molecular docking and all-atom MD simulations, followed by synthesis and biological testing of 18 compounds. Highlights: B14 → strongest activity in HCT-116 B8 → most effective in A375 B18 → potent inhibition in HT-29 B3 → best in TPC-1 All showed activity comparable to sorafenib B4 stood out as the most potent BRAFV600E kinase inhibitor Why it matters: This work showcases how HPC accelerates drug discovery, enabling faster and more precise identification of therapeutic candidates. Drug discovery isn’t just about molecules — it’s about merging minds, models, and machines. Read the work: 🔹 https://lnkd.in/dJ-rzSxU 🙏 Supported by the Croatian Science Foundation (IP-2022-4658) and powered by the Supek supercomputer at SRCE, University of Zagreb. #HPC #DrugDiscovery #CancerResearch #MolecularDynamics #ComputationalChemistry #BRAFV600E

A new review on the cGAS–STING pathway in colorectal cancer cites Insilico Medicine’s ENPP1 program as an example of AI-driven innovations in STING modulator design. We leverage our generative chemistry artificial intelligence-based drug design platform Chemistry42 to facilitate the design of ISM5939, an orally bioavailable ENPP1-selective inhibitor capable of stabilizing extracellular cGAMP and activating bystander antigen-presenting cells without inducing either toxic inflammatory cytokine release or tumor-infiltrating T-cell death. To learn more about ENPP1, click: https://lnkd.in/gSjXNjrM Read the review: https://lnkd.in/gbCQ6K6Y #cGASSTING #STINGPathway #ENPP1 #TumorImmunity #InnateImmunity #ColorectalCancer #CRC #SmallMolecule #Chemistry42

Supercomputer decodes protein ‘language,’ offering new clues to fight cancer. https://hubs.ly/Q03QkpGP0 A new breakthrough explores how an AI-powered supercomputer is helping scientists decode the “language of proteins,” enabling the prediction of protein structure, function, and interactions with unprecedented accuracy. At CovalX, our Immunoprecipitation-Mass Spectrometry (IP-MS) Services translate these predictive insights into experimental validation capturing complex protein interactions, binding partners, and signaling networks with high resolution to support drug discovery and biomarker development. https://hubs.ly/Q03QkqK90

What if we could freeze live cancer tissue and grow it back later for research? That’s exactly what scientists have done. In a new study, researchers improved cryopreservation methods to successfully create patient-derived tumor organoids from 42 frozen tumor samples. These living mini-tumors mimic the real patient’s cancer and can be used to test drugs, study disease progression, and personalize treatments. It’s a powerful reminder that high-quality sample storage doesn’t just preserve tissue, it preserves opportunity for life-changing science. 🔗 Read more: https://lnkd.in/ezDnqJq4 #Cryopreservation #CancerResearch #Biobanking #Organoids #ColdStorage #GenVault #LifeSciences

Great news! The analytical reliability of the scrape-free collection method for our ColoSense® colorectal cancer screening test is validated by new peer-reviewed data in Practical Laboratory Medicine. This innovative, contact-free, single-sample approach simplifies at-home screening by transferring stool handling to the lab. Data indicates high reliability, reproducibility, and a 94% agreement with traditional at-home FIT results. Hear more about this advancement at ACG 2025! Visit Geneoscopy at Booth #565 and check out our poster P2612 on Monday, Oct. 27, 2025, from 10:30 a.m. to 4:00 p.m. PDT. Read the full release here: https://bit.ly/3WCuafm #CRCScreening #ColoSense #GastrointestinalHealth #ACG2025 #Diagnostics

🔬 𝗡𝗮𝗻𝗼𝘁𝘂𝗯𝘂𝗹𝗮𝗿 𝗽𝗲𝗽𝘁𝗶𝗱𝗲𝘀 to overcome chemotherapy resistance   CiQUS researchers have developed a molecular strategy that uses 𝘀𝗲𝗹𝗳-𝗮𝘀𝘀𝗲𝗺𝗯𝗹𝗶𝗻𝗴 𝗰𝘆𝗰𝗹𝗶𝗰 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝗻𝗮𝗻𝗼𝘁𝘂𝗯𝗲𝘀 to transport doxorubicin into 𝗱𝗿𝘂𝗴-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗲𝗹𝗹𝘀, enhancing drug delivery and controlled release inside the tumour environment.   👉 https://lnkd.in/dYax6ahY 📄 Published in 𝘈𝘊𝘚 𝘈𝘱𝘱𝘭𝘪𝘦𝘥 𝘔𝘢𝘵𝘦𝘳𝘪𝘢𝘭𝘴 & 𝘐𝘯𝘵𝘦𝘳𝘧𝘢𝘤𝘦𝘴 Congrats to the authors: Marcos Vilela Picos, Eva Gonzalez Freire, PhD Yeray Folgar-Cameán, José Brea, Manuel Amorín, Juan R. Granja #FondosEuropeos #RedeCIGUS

This week at #ESGCT2025, T-knife Scientist Mira Heichenko presented preclinical data showcasing our MyT™ platform as a powerful engine for discovering high-affinity, next-generation TCR-T therapies for solid tumors.   By combining computational multi-omics workflows with our proprietary humanized in vivo screening, we identified highly immunogenic solid tumor antigens not previously recognized as functional.   We’re excited to advance our lead candidate, TK-6302, a supercharged PRAME T cell receptor therapy, with a Clinical Trial Application (CTA) planned for this year.   Learn more: https://lnkd.in/gcrBqYvp

Precision in IHC starts with the right antibody. @GeneTex's HistoMAX IHC-optimized monoclonal antibodies are extensively validated in IHC tissue arrays. All of these reagents were extensively evaluated using formalin-fixed human normal tissues (more than 70 different sections) and cancer tissue arrays to guarantee specificity and best-in-class performance. ✅ Extensively validated in in IHC tissue arrays ✅ Carrier free version available ✅ Try without risk: 25μl size available for many antibodies Learn more here 👉https://hubs.la/Q03KxxXm0

𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗚𝗮𝘀𝘁𝗿𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿’𝘀 𝗜𝗺𝗺𝘂𝗻𝗲 𝗘𝘃𝗮𝘀𝗶𝗼𝗻 𝗦𝗲𝗰𝗿𝗲𝘁𝘀 𝘄𝗶𝘁𝗵 𝗫𝗲𝗻𝗼-𝗳𝗿𝗲𝗲 𝗩𝗶𝘁𝗿𝗼𝗚𝗲𝗹® 𝗥𝗚𝗗 Researchers used VitroGel® RGD to create 3D invasion assays with HGC27 and MKN45 gastric cancer cells, studying the role of SPTSSA in tumor progression. 𝗩𝗶𝘁𝗿𝗼𝗚𝗲𝗹® 𝗥𝗚𝗗, 𝗮 𝘁𝘂𝗻𝗮𝗯𝗹𝗲 𝘅𝗲𝗻𝗼-𝗳𝗿𝗲𝗲 𝗵𝘆𝗱𝗿𝗼𝗴𝗲𝗹, mimicked the 3D tumor environment, showing that SPTSSA overexpression increases invasiveness, while knockdown reduces it, highlighting VitroGel® RGD’s value for modeling gastric cancer. 📑 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁: https://lnkd.in/ebXbFcYN ➡️ For more 3D tumor modeling insights with VitroGel®, visit: https://lnkd.in/e5mmH33m #3DCellCulture #InvasionAssay #GastricCancer #CancerResearch #Biotechnology #VitroGel #CellCulture #LifeSciences #LabInnovation #Biotech #Research

CAPS Medical’s PlasmaSure™ Receives FDA Breakthrough Device Designation https://lnkd.in/gV4PxN-K Breakthrough designation for Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) supports CAPS Medical’s mission to transform tumor ablation into a simple, selective, and in-office procedure SANTA MONICA, Calif. and NETANYA, Israel, Oct. 15, 2025 /PRNewswire/ [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News